RadNet (RDNT) shares recently reacted to first quarter earnings, where revenue reached US$575.63 million compared with US$471.4 million a year earlier, while the company reported a narrower net loss of US$33.47 million.

The earnings release appears to have come during a weaker spell for the stock, with the 30 day share price return down 11.66% and the year to date share price return down 24.81%. However, the 3 year total shareholder return of 88.05% and 5 year total shareholder return of 102.85% still point to a strong longer term payoff for investors who stayed invested.

If RadNet’s recent move has you revisiting where growth could come from next, it may be worth scanning other healthcare related AI opportunities through our curated list of 29 healthcare AI stocks.

With RadNet shares down 24.81% year to date and trading at a 41.15% discount to one intrinsic value estimate and 31.77% below the average analyst target, is there a genuine opportunity here, or is the market already factoring in future growth?

Most Popular Narrative: 40.6% Undervalued

RadNet’s most followed narrative sets a fair value of $89.88 per share versus the last close of $53.35. It frames a wide gap that hinges on its imaging platform and digital health rollout.

Ongoing investments in AI-powered imaging solutions (e.g., DeepHealth, See-Mode, iCAD) are materially increasing center throughput, boosting capacity utilization, and driving more high-margin advanced procedures, directly enhancing both revenue growth and EBITDA margins as adoption scales through 2026.

Curious what kind of revenue path, margin shift, and future earnings multiple would need to line up to support that higher fair value? The full narrative lays out a detailed roadmap of expected growth in imaging volumes, profitability, and valuation assumptions that go well beyond a simple price target.

Result: Fair Value of $89.88 (UNDERVALUED)

However, this hinges on RadNet keeping imaging demand and reimbursement support on track, as well as avoiding cost overruns or delays as new AI platforms are integrated.

Another View: What The Ratios Are Saying

That 40.6% DCF style undervaluation signal is only one angle. On revenue, RadNet trades on a P/S of about 2x, which is higher than the US Healthcare sector at 1.3x and more than double the 0.9x fair ratio estimate. If revenue stumbles or sentiment cools, that premium could narrow quickly.

For a closer look at how the numbers line up against peers and that fair ratio, See what the numbers say about this price — find out in our valuation breakdown.

Next Steps

With mixed signals on valuation and sentiment, this is a moment to move quickly, review the data for yourself, and weigh up the 3 key rewards and 2 important warning signs.

Looking for more investment ideas?

If RadNet has you thinking more broadly about where to put your money to work next, do not stop here. Broaden your watchlist before the next move passes you by.

• Hunt for potential bargains by scanning 54 high quality undervalued stocks that pair quality with prices that may not fully reflect underlying fundamentals.
• Prioritize resilience by reviewing 66 resilient stocks with low risk scores that score well on stability and may help balance out more volatile positions.
• Spot early opportunities by checking the screener containing 21 high quality undiscovered gems that sit off most investors’ radar but still show solid financial underpinnings.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.